[Autologous haematopoietic stem cell transplantation in patients with multiple myeloma complicated by dialysis-dependent renal failure].
Maiia SolovevaL P MendeleevaM V SolovevI G RekhtinaO S PokrovskayaE S UrnovaN P SobolevaValentina DvirnykGalina KlyasovaLarisa A KuzminaS M KulikovPublished in: Terapevticheskii arkhiv (2020)
Carrying out auto-HSCT in patients with dialysis-dependent renal failure contributed to the achievement of a minimal renal response in 14% of cases, which allowed these patients to stop hemodialysis. Patients whose conditioning regimen was performed using melphalan at a dose of 200 mg/m2showed more frequent complications in the early post-transplant period compared to patients who received a lower dose of melphalan (100140 mg/m2). Auto-HSCT in MM patients with dialysis-dependent renal failure is a feasible and effective treatment method, which in some cases contributes to independence from hemodialysis.